Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 3/20 | 0.54 |
| ▸ | PNMT | P11086 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30719147 | 1.00 | IDO1 (0.54) | IDO1PNMTTAAR1KMT2ALMNA | |
| Bromide SCHEMBL5111064 | 0.95 | IDO1 (0.54) | IDO1PNMTTAAR1LMNATSHR | |
| Hydrochloric Acid SCHEMBL1043017 | 0.80 | PNMT (0.60) | IDO1PNMTTAAR1TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL4204405 | 0.78 | PNMT (0.41) | IDO1PNMTTAAR1CYP1A2CYP3A4 | |
| Pivalate SCHEMBL9953463 | 0.77 | NPC1 (0.43) | IDO1PNMTLMNATSHRPKM | |
| Bromide SCHEMBL11300757 | 0.75 | PNMT (0.60) | IDO1PNMTTAAR1TSHRCYP1A2 | |
| SCHEMBL29519238 | 0.75 | IDO1 (0.62) | IDO1PNMTTAAR1LMNATSHR | |
| SCHEMBL6740216 | 0.75 | TAAR1 (0.71) | IDO1PNMTTAAR1KMT2ALMNA | |
| SCHEMBL672407 | 0.75 | IDO1 (0.62) | IDO1PNMTTAAR1LMNATSHR | |
| Hydrochloric Acid SCHEMBL27898437 | 0.74 | IDO1 (0.54) | IDO1PNMTTAAR1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2024-10-31 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | VESTLANDETS INNOVASJONSSELSKAP AS (NO) | 2023-07-20 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005121130-A2 | CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005068447-A1 | PIPERAZINE DERIVATIVES WHICH EXHIBIT ACTIVITY AS SEROTONIN AND NORADRENALINE RE-UPATKE INHIBITORS | PFIZER LIMITED (GB) | 2005-07-28 | — | — | WO | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DANA-FARBER CANCER INSTITUTE | 2004-12-30 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2003031458-A1 | METHODS FOR SYNTHESIS OF DIARYLMETHANES | DANA-FARBER CANCER INSTITUTE (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | CHRM2 257/4885SLC6A2 4675/4885SLC6A3 4670/4885 |
| US-20240360140-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | CHRM2 283/4885SLC6A2 842/4885SLC6A3 1257/4885 |
| US-20040267011-A1 | Methods for synthesis of diarylmethanes | DHFR, DPYD, DHODH | CHRM2 4285/4885SLC6A2 2281/4885SLC6A3 1831/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | CHRM2 512/4885SLC6A2 860/4885SLC6A3 693/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CHRM2 241/4885SLC6A2 2705/4885SLC6A3 2950/4885 |
| US-20230192696-A1 | SPIRO COMPOUNDS AS INHIBITORS OF KRAS | KRAS, HRAS, NRAS | CHRM2 4877/4885SLC6A2 4828/4885SLC6A3 4451/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | CHRM2 241/4885SLC6A2 2705/4885SLC6A3 2950/4885 |
| US-20230225991-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE INTERMITTENT PORPHYRIA | HMBS, POR, CYP2A13 | CHRM2 1549/4885SLC6A2 3689/4885SLC6A3 2744/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | CHRM2 283/4885SLC6A2 842/4885SLC6A3 1257/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | CHRM2 3389/4885SLC6A2 4512/4885SLC6A3 4496/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | CHRM2 242/4885SLC6A2 4102/4885SLC6A3 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.